ADDENDUM TO ASSET PURCHASE AGREEMENTAddendum to Asset Purchase Agreement • January 25th, 2019 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of April 12, 2016 by and between Novartis Pharma AG, a Swiss company (“Novartis”) and Mereo BioPharma 1 Limited, a private limited company incorporated in England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively ‘‘Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma 1, and “Party” shall mean either Novartis or Mereo Biopharma l, as the context requires.
ADDENDUM TO ASSET PURCHASE AGREEMENTAddendum to Asset Purchase Agreement • January 25th, 2019 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of October 4, 2017 by and between Novartis Pharma AG, a Swiss company (“Novartis”) and Mereo BioPharma 1 Limited, a private limited company incorporated in England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively “Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma l, and “Party” shall mean either Novartis or Mereo Biopharma l , as the context requires.
ADDENDUM TO ASSET PURCHASE AGREEMENTAddendum to Asset Purchase Agreement • January 25th, 2019 • Mereo Biopharma Group PLC • Pharmaceutical preparations
This Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of August 17, 2017 by and between Novartis Pharma AG, a Swiss company (“Novartis”) and Mereo BioPharma 2 Limited, a private limited company incorporated in England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively “Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma 2, and “Party” shall mean either Novartis or Mereo Biopharma 2, as the context requires.
ADDENDUM TO ASSET PURCHASE AGREEMENTAddendum to Asset Purchase Agreement • January 25th, 2019 • Mereo Biopharma Group PLC • Pharmaceutical preparations • New York
This Addendum to Asset Purchase Agreement (“Addendum”) is entered into as of December 21, 2016 by and between Novartis Pharma AG, a Swiss company (“Novartis”) and Mereo BioPharma 3 Limited, a private limited company incorporated in England and Wales, and a wholly owned subsidiary of Mereo BioPharma Group Limited, a company incorporated in England and Wales (collectively “Mereo”). Hereinafter “Parties” shall mean Novartis and Mereo Biopharma 3, and “Party” shall mean either Novartis or Mereo Biopharma 3, as the context requires.
